×

CNBC EXCLUSIVE: CNBC TRANSCRIPT: CNBC'S MIKE HUCKMAN INTERVIEWS DR. MITCHELL GOLD, DENDREON CEO TODAY ON CNBC'S "SQUAWK ON THE STREET"

WHEN: TODAY, TUESDAY, APRIL 14TH

WHERE: CNBC'S "SQUAWK ON THE STREET"

Following is the unofficial transcript of a CNBC EXCLUSIVE interview with Dendreon CEO Dr. Mitchell Gold today on CNBC's "Squawk on the Street."

All references must be sourced to CNBC.

----------------------------------------------------------------

BURNETT: HEALTH CARE HEADLINES DENDREON A NAME IN THE NEWS AND LET'S GET TO MIKE WITH A SPECIAL INTERVIEW HERE. MIKE TAKE IT AWAY.

HUCKMAN: THOSE SHARES BY THE WAY ARE SURGING BIG TIME ON VERY HEAVY VOLUME AND FRESH OFF THE COMPANY'S CONFERENCE CALL FROM DENDREONS HEADQUARTERS IN SEATTLE. I AM JOINED LIVE BY THE COMPANY'S CEO DR MITCHELL GOLD FOR THIS EXCLUSIVE TV INTERVIEW ALBEIT OVER THE PHONE. HE IS A MD BY THE WAY A FORMER PRACTICING UROLOGIST.DR. GOLD, GOOD MORNING.

DR. GOLD: GOOD MORNING MIKE.

HUCKMAN: I IMAGINE YOU DIDN'T GET MUCH SLEEP, BUT YOUR ADRENALINE HAS TO BE PUMPING AND YOU MUST BE ON CLOUD NINE I SUSPECT.

DR. GOLD: WE ARE ABSOLUTELY THRILLED WITH THE RESULTS. THIS IS A LANDMARK STUDY THE FIRST ACTIVE IMMUNOTHERAPY TO SHOW A SURVIVAL BENEFIT IN A PHASE THREE STUDY AND A TREMENDOUS ACCOMPLISHMENT FOR THE COMPANY BUT IT MEANS A TREMENDOUS AMOUNT FOR PROSTATE CANCER PATIENTS ACROSS THE WORLD.

HUCKMAN: EXPLAIN WHAT ACTIVE IMMUNOTHERAPY MEANS AND HOW IT DIFFERS FROM CHEMOTHERAPY WHICH EVERYBODY KNOWS SO WELL.

DR. GOLD: SURE WELL THIS IS A LONG SOUGHT AFTER APPROACH OF USING A PATIENT'S OWN IMMUNE SYSTEM TO FIGHT CANCER. AND WHAT WE DO WITH PROVENT WHICH IS OUR LEAD PRODUCT THAT WE REPORTED ON TODAY IS USE A PATIENT'S OWN IMMUNE SYSTEM CELLS AND ACTIVATE THEM AGAINST THE PATIENT'S OWN PROSTATE CANCER AND WE ARE ABLE TO ALLISIT AN IMMUNE RESPONSE AND TODAY WHAT WE REPORTED IS THAT WE SHOW A SURVIVAL BENEFIT WHICH IS A GOLD STANDARD OUTCAME IN ONCOLOGY CLINICAL TRIALS IN A LARGE RANDOMIZED FACE RETRIAL. FOR THE PATIENT'S PERSPECTIVE ASYOU SAID, ONE OF THE DEBILITATING SIDE EFFECTS OF CHEMOTHERAPY IS HAIRLOSS NAUSEA VOMITING ETC AND IN CONTRAST TO THAT PROVENT IS FAIRLY WELL TOLERATED AND THE MOST COMMON SIDE EFFECT IS FEVERS ANDCHILLS THAT LAST ONE OR TWO DAYS AND THERE IS A SHORT DURATION.

HUCKMAN: ON THE CONFERENCE CALL YOU SAID THAT THE POSITIVE RESULTS ARE UNAMBIGUOUS. THAT'S YOUR WORD AND THAT THE STUDY WAS A CLEAR HIT. YOU WILL BE PRESENTING THE DETAILED DATA AT THE UPCOMING UROLOGICAL ASSOCIATION MEETING IN CHICAGO ON APRIL 28thIN THE AFTERNOON. CAN YOU TELL US, DOES THIS MEAN YOU MET THAT THRESHOLD OF AT LEAST A 22% REDUCTION IN THE RISK OF DEATH THAT YOU WOULD EARLIER IDENTIFY AS THE THRESHOLD THAT YOU NEEDED TO MEET OR CROSS TO POSSIBLY WIN FDA APPROVAL OF THIS PRODUCT?

DR. GOLD: SURE. IT WAS UNAMBIGUOUS IN THE PHASE THREE STUDY DESIGN THAT WE MET A PRESPECIFIED POINT OF THE STUDY IN THE IMPROVEMENT OF OVERALL SURVIVAL. THAT DATA WE PRESENTED IN FULL AT A MAJOR ACADEMIC MEDICAL CONFERENCE CALLED THE MEDICAL NEUROLOGICAL SOCIETY WHERE ALL THE NEUROLOGISTS COME TOGETHER. BECAUSE OF MEDICAL SIGNIFICANCE OF THIS TRIAL, IT'S IMPORTANT THAT THOSE RESULTS ARE EMBARGOED UNTIL IT PRESENTED IN MAJOR MEDICAL FORUM SUCH AS THE AUA. THIS IS THE FIRST ACTIVE IMMUNOTHERAPY TO SHOW A SURVIVAL BENEFIT IN CANCER AND ONE OF THE LONGEST FOLLOWUPS WE'VE HAD IN THIS PATIENT POPULATION SO ITS OF MAJOR SIGNIFICANCE TO THE MEDICAL COMMUNITY.

HUCKMAN: NATURALLY EVERYONE WANTS TO WHEN THEY CAN GET IT. PEOPLE HERE AT CNBC ARE ASKING WHEN WILL THIS DRUG BE AVAILABLE?BEST CASE SCENARIOS WHEN CAN YOU WIN FDA APPROVAL AND GET THE PRODUCT ON THE MARKET?

DR GOLD: AS WE SAID IN THE CALL TODAY, THE COMPANY PLANS TO COMPLETE THE APPLICATION WITH THE U.S. FOOD AND DRUG ADMINISTRATION IN THE FOURTH QUARTER OF THIS YEAR. THE FDA WILL HAVE SIX MONTHS TO REVIEW THE APPLICATION AFTER OUR SUBMISSION.

HUCKMAN: YESTERDAY YOUR STOCK WAS UP ABOUT 16% OR A BUCK OR SO ON HEAVY VOLUME. YOU DID NOT PUT OUT THE PRESS RELEASE UNTIL AFTER THE MARKETS CLOSED.YOU WERE GOING TO ANNOUNCE THE NEW DATA THIS MORNING. WAS THERE A LEAK?

DR GOLD: WE ARE NOT AWARE OF A LEAK AND WE PUT THE RESULTS OUT IN A TIMELY FASHION.

HUCKMAN: YOU ARE WELL AWARE OF THE ENVIRONMENT IN BIOPHARMA.BIG PHARMA NEEDS DRUGS AND SMALLBIOTECHS LIKE YOURS HAVE THE DRUGS AND NEED THE MONEY. DO YOU EXPECT THAT POTENTIAL SUITORS WILL BANG DOWN YOUR DOOR TO TRY TO PARTNER OR BUY YOUR COMPANY OUT RIGHT NOW?

DR GOLD: WELL DENDREON FINDS ITSELF IN A UNIQUE POSITION. WE WERE FIRST IN CLASS PRODUCT POTENTIALLY WITH PROVENGE, BUT IT'S BASED ON A PLATFORM TECHNOLOGY.WE HAVE OTHER PRODUCTIONS IN THE PIPELINE THAT TARGET BREAST, COLORECTAL AND KIDNEY CANCER. WE ARE IN A UNIQUE POSITION THAT WE'VE NOW RECEIVED POSITIVE DATA FROM A PHASE THREE STUDY IN PROVENGE WE'VE MADE IT PUBLIC THAT WE PLAN TO SEEK A COMMERCIALIZATION PARTNER OUTSIDE THE US AND COMMERCIAL PRODUCT OURSELVES IN THE U.S.

HUCKMAN: THANKS AGAIN DR. MITCHELL GOLD THE CEO OF DENDREON WHOSE SHARES ARE UP ABOUT 180%. WE LOOK FORWARD TO TALKING TO YOU AT THE AUA MEETING AT THE END OF THIS MONTH. FOR MORE, CHECK OUT MY BLOG AND YOU CAN FOLLOW ME ON TWITTER AT M HUCKMAN. BACK TO YOU.




About CNBC:
CNBC is the recognized world leader in business news, providing real-time financial market coverage and business information to more than 340 million homes worldwide, including more than 95 million households in the United States and Canada. The network's Business Day programming (weekdays from 5:00 a.m.-7:00 p.m. ET) is produced at CNBC's headquarters in Englewood Cliffs, N.J., and also includes reports from CNBC news bureaus worldwide. Additionally, CNBC viewers can manage their individual investment portfolios and gain additional in-depth information from on-air reports by accessing http://www.cnbc.com.

Members of the media can receive more information about CNBC and its programming on the NBC Universal Media Village Web site at http://nbcumv.com/cnbc/.